<SEC-DOCUMENT>0001387131-19-004260.txt : 20190607
<SEC-HEADER>0001387131-19-004260.hdr.sgml : 20190607
<ACCEPTANCE-DATETIME>20190607071529
ACCESSION NUMBER:		0001387131-19-004260
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190606
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190607
DATE AS OF CHANGE:		20190607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		19884168

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_060619.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: center">Date of Report (Date of earliest event
reported): June 6, 2019</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center"><B>TherapeuticsMD, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.5pt; padding-left: 5.5pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Exact Name of Registrant as Specified in its Charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">jurisdiction of incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant's telephone number, including area
code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: justify">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.3pt; text-align: justify; text-indent: -14.3pt"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.3pt; text-align: justify; text-indent: -14.3pt"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt MS Mincho; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">TXMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Item 1.01. Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">On June 6, 2019,
TherapeuticsMD, Inc., a Nevada corporation (the &#8220;Company&#8221;), entered into a Licensing and Supply Agreement (the &#8220;Licensing
Agreement&#8221;) with Theramex HQ UK Limited, a company formed under the laws of England (&#8220;Theramex&#8221;), pursuant to
which the Company granted Theramex an exclusive, perpetual license to commercialize for human use the Company&#8217;s FDA-approved
products BIJUVA&#8482; (estradiol and progesterone capsules) and IMVEXXY&reg; (estradiol vaginal inserts) outside of the United
States, except for Canada and Israel, for which the Company has licensed BIJUVA&#8482; and IMVEXXY&reg; to Knight Therapeutics
(such licensed area to Theramex, the &#8220;Territory&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Pursuant to the
terms of the Licensing Agreement, Theramex will pay the Company an upfront fee of EUR 14 million in cash within 60 days of entering
into the Licensing Agreement. The Company is also eligible to receive up to an additional EUR 29.5 million in cash milestone payments,
comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA&#8482;
and IMVEXXY&reg; in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid
in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory
ranging from EUR 25 million to EUR 100 million. The Company is also entitled to receive quarterly royalty payments based on net
sales of BIJUVA&#8482; and IMVEXXY&reg; in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Theramex will be
responsible for all regulatory and commercial activities in the Territory related to BIJUVA&#8482; and IMVEXXY&reg;. Theramex has
agreed to submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA&#8482; and IMVEXXY&reg; in certain specified markets within certain specified time periods and the Company may terminate
the Licensing Agreement if Theramex does not submit certain of such regulatory applications, submissions and/or registrations.
The Company may also terminate the Licensing Agreement if Theramex challenges the Company&#8217;s patents. Either party may terminate
the Licensing Agreement for any material breach by the other party that is not cured within certain specified time periods or if
the other party files for bankruptcy or other related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Theramex may sublicense
its rights to commercialize BIJUVA&#8482; and IMVEXXY&reg; in the Territory, except for certain specified markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Pursuant to the
terms of the Licensing Agreement, the Company has agreed to supply, or cause to be supplied, BIJUVA&#8482; and IMVEXXY&reg; to
Theramex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The Company and
Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Licensing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The foregoing summary
of the terms of the Licensing Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the
full text of the Licensing Agreement, a copy of which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form
10-Q for the quarter ending June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 48pt; text-align: justify; text-indent: -48pt"><B>Item 7.01
Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">On June 7, 2019,
the Company issued a press release announcing that it had entered into the Licensing Agreement. A copy of the press release is
attached as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The information
being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 hereto shall not be deemed to be &#8220;filed&#8221;
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor will any of such information or exhibits be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0in"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.25in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0in">Exhibit Index</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 83%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ex99-1.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press Release, dated June 7, 2019, issued by TherapeuticsMD, Inc. titled TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA&#8482; and IMVEXXY&reg; Outside the United States.</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: June 7, 2019</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_060619.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><IMG SRC="therapeuticsmd-logo.jpg" ALT="" STYLE="height: 28px; width: 239px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FOR IMMEDIATE RELEASE </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TherapeuticsMD and Theramex Enter into
Exclusive License and Supply Agreement to <BR>
Commercialize BIJUVA&trade; and IMVEXXY&reg; Outside the United States</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">-Agreement leverages Theramex&rsquo;s
extensive women&rsquo;s health capabilities and infrastructure to the <BR>
benefit of menopausal women outside of U.S.-</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">-TherapeuticsMD to receive EUR 14 million
as an upfront fee and is eligible to receive up to EUR 29.5 million <BR>
in regulatory and sales milestone payments, as well as a royalty
on net sales -</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BOCA RATON, Fla., June 7, 2019</B>
&ndash; TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women&rsquo;s healthcare company, today announced that it has
entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated
to women&rsquo;s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts)
outside of the United States. Theramex is a portfolio company of CVC Capital Partners.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Theramex
will have exclusive commercialization rights for BIJUVA and IMVEXXY outside the U.S., excluding Canada and Israel, for which TherapeuticsMD
has licensed BIJUVA and IMVEXXY to Knight Therapeutics. Theramex will be responsible for conducting all regulatory and commercial
activities in connection with </FONT>BIJUVA and IMVEXXY in the licensed territories<FONT STYLE="background-color: white">. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Under
the terms of the license and supply agreement, Theramex will pay TherapeuticsMD EUR 14 million in cash as an upfront fee. TherapeuticsMD
is eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2
million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets
and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on first attaining
certain aggregate annual net sales milestones </FONT>in the licensed territories <FONT STYLE="background-color: white">ranging
from EUR 25 million to EUR 100 million. TherapeuticsMD is also entitled to receive royalty payments on net sales of BIJUVA and
IMVEXXY </FONT>in the licensed territories<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&quot;We
are very pleased to announce our partnership with Theramex to bring BIJUVA and IMVEXXY to women outside of the United States,&rdquo;
said Robert G. Finizio, CEO of TherapeuticsMD. &ldquo;We believe this agreement provides our company with important non-dilutive
upfront capital to help fund our product launches in the United States as well as an incremental royalty stream to support future
growth.&rdquo;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Anish
Mehta, CEO of Theramex, said, &ldquo;This partnership with TherapeuticsMD marks another exciting milestone in the execution of
our women&rsquo;s health growth strategy. By leveraging our best in class commercial capabilities and global footprint, we intend
to rapidly commercialize these novel and innovative medicines for women around the world.&rdquo; </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;BIJUVA
and IMVEXXY strengthens Theramex&rsquo;s already exciting range of women&rsquo;s health treatment options for doctors and their
patients,&rdquo; said Fred Hassan, Chairman of Theramex.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional information concerning the
license and supply agreement is contained in the Form 8-K filed by TherapeuticsMD today with U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Copies of the U.S. Full Prescribing Information, including
Boxed Warnings, for BIJUVA and IMVEXXY are available at https://www.bijuva.com/pi.pdf and www.imvexxy.com/pi.pdf, respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Theramex</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Theramex is a leading, global specialty
pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering
contraception, fertility, menopause and osteoporosis, Theramex supports women at every stage of their lives. Theramex&rsquo;s commitment
is to understand its patients, serve their needs, and offer healthcare solutions to help improve their lives. Theramex&rsquo;s
vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing innovative, effective
solutions that care for and support women as they advance through each stage of their lives. To learn more about Theramex, please
visit www.theramex.com.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About&nbsp;TherapeuticsMD, Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc.&nbsp;is an innovative,
leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed
to <FONT STYLE="background-color: white">address the unique changes and challenges women experience through the various stages
of their lives with a therapeutic focus in family planning, reproductive health, and menopause management</FONT>. The company is
c<FONT STYLE="background-color: white">ommitted to advancing the health of women and championing awareness of their healthcare
issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on
Facebook: TherapeuticsMD.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 9.6pt"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 9.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
press release by&nbsp;TherapeuticsMD, Inc.&nbsp;may contain forward-looking statements. Forward-looking statements may
include, but are not limited to, statements relating to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as
statements, other than historical facts, that address activities, events or developments that the company intends, expects,
projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology
such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions
and assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release
are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important
factors that could cause actual results, developments and business decisions to differ materially from
forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings
with the&nbsp;Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q, as well as reports on Form 8-K, and include the following: the company&rsquo;s ability to maintain or increase
sales of its products; the company&rsquo;s ability to develop and commercialize IMVEXXY<SUP>&reg;</SUP>,
ANNOVERA<SUP>&trade;</SUP>, BIJUVA<SUP>&trade;</SUP> and its hormone therapy drug candidates and obtain additional financing
necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan
facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of
the company&rsquo;s current or future approved products or preclude the approval of the company&rsquo;s future drug
candidates; the length, cost and uncertain results of future clinical trials; the company&rsquo;s reliance on third parties
to conduct its manufacturing, research and development and clinical trials; the ability of the company&rsquo;s licensees to
commercialize and distribute the company&rsquo;s products; the availability of reimbursement from government authorities and
health insurance companies for the company&rsquo;s products; the impact of product liability lawsuits; the influence of
extensive and costly government regulation; the volatility of the trading price of the company&rsquo;s common stock and the
concentration of power in its stock ownership. PDF copies of the company&rsquo;s historical press releases and financial
tables can be viewed and downloaded at its website:&nbsp;www.therapeuticsmd.com/pressreleases.aspx.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt"><B><U>Investor Contact</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Nichol Ochsner</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">561-961-1900, ext. 2088</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Nochsner@TherapeuticsMD.com</P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>therapeuticsmd-logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 therapeuticsmd-logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#J-8^'NL:7
MHM]J \<ZQ(;6WDF"%W&[:I.,[_:J'A#P;K/B?PS:ZL_C76+=IR^8Q([ ;6*]
M=X]*]-\6_P#(FZW_ ->,W_H!K$^$_P#R3C3/K+_Z,:NE59>S;\^R_P CE=*'
MM%'I;N^_J<[XFLWTSQKX M)KM[EK<LKW$I^9\%<L<D_SKM(_'OA66^%DFN6A
MG+;0-Q"D^@;[OZUQ?Q0TV+6/&WA+3IV98;AWCD*G!VEER!^%;?B_P)X<_P"$
M,U 6VE6MM+:VSRPRQ)M=649Y;J<XYSFA\K4>;K_F)<\93Y+:?Y'=USD_C[PI
M;WAM)=<M!*#M.&)4'W8# _.O.]7\37T/P,TEA.ZSWC_8WES\WEJ7!Y]P@'T)
MJ:QUSX56>AKI;6ZSJ4VR3263&1SW;=C(/T/':DJ.EW=^A3KZV5EI?4];>[MT
MLFO&GC^S+&93-N!78!G=GTQS67<>+?#]IID.HS:O:K:3$B*3?GS,'!V@<G!!
MZ5YGX&U59?!WC/1X+B2XL+."9[.212#Y;(_'/3H#CU)I_P ,/ >GZSX?BUC7
M(S>ABT5I!(QV1HK')P.N6W>WYT.E&-W)[ JTI64%NCTW4?$^AZ1"DNH:I;6X
MD4.@=_F8'G(7K^E)H_BC0]?9ETO4[>Y=1DHK88#UVG!Q7'>+M3\%VOB*.VN=
M!?6=9CA6(6]O#YFQ.J@@G&>?0GI7$ZUJ.FV_B#0K_2?#>H>'[^*[19%D@\J.
M1">P[GJ.@R":(T5)=?P_X<4Z[B^EOG_PQ[A+K6F0:@;":^MX[L1F4Q.X!"#J
MQ]N*R[;QYX6N[T6D&MVC3$[5!8@,?0,1@_G7!^)M!B\1_&NVT^YD=;4V*O,J
M,5+JNX[<^YQ78:Y\//#FI:%-9PZ7:VLJQMY$T,85D;J"2.2,]0:GD@K7;U*4
MZDF^5+0ZZN>O/'?A>PO39W.M6J3J=K*"6"GT) ('XUYI%XRU&/X'O)Y[B\6Y
M_LY9\_,%QNSGUVY7-3Z+KGPOTS08M/GMTN9#&!/-+9,SN^.3DC(YZ8Z52HVO
M>[]"7B+VM9:7U/7&U"S73VU W47V-8S*9PX*; ,[L^E+97UKJ-G'=V4\<]O)
MDI)&<JV#@X/U!KQ7PMJ</_".^.M'T^>6;28K26>R,@(*J58$<_A^()[UZ+\,
M?^2<Z/\ [C_^C&J9TN1-_P!;%TZW.TO+];'0'6-.&I/IQO8?ML<?FO!N^8+Z
MX].:\]TGX@6I^(VM1WFOP?V(L*_9-S@1[L)G!QS_ !?K4L*A_CW>*P!4Z8 0
M>XPM9FA>&]$G^+WB/3Y=*LWLX+=&B@:(%$.(^0.W4_G5QA%)W[7(E.<FK=['
M8>+!IGB+P@LZ^(%L+$RJXOHFRIP2N,Y'?C\*Z"TDM['1;=Y+Q&MHH$S<R, &
M4*/F)/KUKB_BC96NG_#"YM;.WCM[>.6+9'&H55S(#P![FL/6]_B;Q#X2\'R3
M/'IQL8[JZ5#CS,(2!^2_^/>U2H<T5KIJ.53EF]-;([FW\?\ A2ZNQ:Q:Y:F4
MG W$JI/LQ&/UK=N[VUL+1[J[N(H+>,9:21@J@?4US^H?#WPOJ&E'3_[(MK=0
MI$<L$861#ZANI/USFN;^(GAJ\A\)Z-;:7;3W]CIDRM<6I<L\R =^Y[CCINX'
M%2HPDTDRW*I&+;2?H=9I_C;PUJMR+:SUFUDF)PJ%MA8^V[&?PK)^(%QJ<,NC
MII4TJ7#S/M6-\;R-I (Z'Z&L'2M3^&_BB[M+6728-/U"-U\N&6$0G<#PNY>&
M^AZ^E=/XL_Y&'PQ_U]G_ -EJXQ49K3ON<V)DYT'KU6J]4;'A[6HM>TB*\C 6
M3[DT?]QQU']?H:YKQ[K]W#$^E:2[BY6/S[F2-L&*,>_8GC]/6DUPW'@S6I-9
ML;<S6-\"MQ O19N=K?B?YGU%-ET6;3_ VKWM^=^J7T9EN&/5>>$_#_/04XQB
MI*?1[?UY?Y&-:K5G3E1VDD[OR2TM_B_#43Q'=W:_#[198[NXBFE-N'E20ASF
M,YR>IJ]_PAE]""]IXHU59@/E,LA=?Q&:S/$?_).M _WK;_T6:]"I2DXQ5N[+
MI4HU:CY^D8]7V\F<AINO:LMS=:#J*1#6(X]]O,.$G7U],]_P/3%=-IYNS91_
M;0OVC^+;TKE?$V?^$\\,>3CSMTF_UV<?TW?K79U%2UDTMS?#<W-*,FWRNWRL
MGKYK8R?%$,EQX3UB&&-I)9+*941!DL2AP .YK'^&5G<V'@'3[:\MY;>=#)NC
ME0JPS(Q&0:ZZBHYO=Y3HY/?YCS_QGIU[=?$+PA<V]I/+!!*QFD2,LL8ROWB.
M!^-=9XEBDG\+:M%#&TDKV<RHBC)8E#@ >M:E%-SO;R!0MS>?^5CRVQ\&W>N?
M!JRTF6)[74H'>>%)U*$.'? (/3()_,&I+7XA7^GVBV>M>#M2;58P$8P0 QRM
MTW9[9]LBO3J*KVM[\RN1[&UN5VTL<7:2>(-4\#:Y+J^E0V=S<6\XMK: $R;"
MAVJP_O9__4*G^&=G<V'@#3;:\MY;>=/-W1RH589D8C(/M76T5+G=-6*5.S3O
MTL>4R2:CX#^(&LZM<:+=:CIVJ89+BT3>T?.=I';\2.@-4/%^I^(/&3:1)9^&
M]0M]*@O$?=-$?,=O[VT=% SSTYZU[+15JK9IVU(=!M./-H>/>+'U>'XSV]SH
MD237D%@)/(=L>:@W;E^I&<5I:C\0M<U6RDTS1O">J0ZI,IC+3IA82>"<^WJ<
M"IIO^2^V_P#V#3_)J])JI224;J^A$(2DY6E;5GGL/PXQ\+CX:>5!?-_I!EZJ
M)\Y_+ VY].:H6'CK4=#L4TW7_"6HR:A;H(Q+;0ATFQP&S[^V?Z5ZC14>UO\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
